Barclays Releases a Buy Rating on Evolus (EOLS)
TipRanks (Mon, 6-May 4:36 AM ET)
Evolus to Report First Quarter Financial Results on May 7, 2024
Business Wire (Tue, 23-Apr 4:30 PM ET)
Business Wire (Wed, 17-Apr 4:05 PM ET)
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Fri, 12-Apr 4:05 PM ET)
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Business Wire (Tue, 26-Mar 8:00 AM ET)
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
Business Wire (Mon, 11-Mar 7:00 AM ET)
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
Business Wire (Thu, 7-Mar 4:05 PM ET)
Evolus Announces Results from European Head-to-Head Filler Trial
Business Wire (Fri, 1-Mar 8:30 AM ET)
Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences
Business Wire (Tue, 27-Feb 8:30 AM ET)
Business Wire (Thu, 22-Feb 4:30 PM ET)
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
Evolus trades on the NASDAQ stock market under the symbol EOLS.
As of May 6, 2024, EOLS stock price climbed to $13.32 with 163,825 million shares trading.
EOLS has a beta of 1.19, meaning it tends to be more sensitive to market movements. EOLS has a correlation of 0.07 to the broad based SPY ETF.
EOLS has a market cap of $833.75 million. This is considered a Small Cap stock.
Last quarter Evolus reported $61 million in Revenue and -$.12 earnings per share. This beat revenue expectation by $939,000 and missed earnings estimates by -$.05.
In the last 3 years, EOLS stock traded as high as $15.43 and as low as $5.06.
The top ETF exchange traded funds that EOLS belongs to (by Net Assets): VTI, IWM, VXF, IWO, VHT.
EOLS has outperformed the market in the last year with a price return of +60.3% while the SPY ETF gained +27.8%. However, in the short term, EOLS had mixed performance relative to the market. It has underperformed in the last 3 months, returning -1.1% vs +4.4% return in SPY. But in the last 2 weeks, EOLS shares have fared better than the market returning +15.5% compared to SPY +4.0%.
EOLS support price is $12.96 and resistance is $13.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EOLS stock will trade within this expected range on the day.